Croda acquires market-leading vaccine adjuvant specialist

17 Dec 2018

Croda will not only gain ownership to Biosector’s rich development pipeline but will become the only adjuvant supplier in the world with an aseptic and GMP-certified manufacturing site for vaccine adjuvants.

Croda International has strengthened its pharmaceutical offering by signing a definitive agreement with Brenntag Nordic to acquire Brenntag Biosector (Biosector), for a total consideration of €72 million in cash. This transaction is expected to close by the end of 2018.

Croda acquires market-leading vaccine adjuvant specialist

Founded in 1939, Biosector has unprecedented industry experience as a vaccine adjuvant specialist, with their product portfolio comprising innovative aluminium- and saponin-based adjuvants. The Biosector team, based in Frederikssund, Denmark will be welcomed to the Croda group and continue to be led by Managing Director Peter Tygesen.

Vaccine adjuvants are a complimentary extension of Croda’s existing pharmaceutical excipients portfolio within their Health Care business. The acquisition of Biosector will give Croda access to an industry renowned product portfolio of adjuvants, including the well-known brands Alhydrogel and Adju-Phos, as well as their technically advanced saponin-based adjuvant systems. Through this acquisition, Croda will not only gain ownership to Biosector’s rich development pipeline for second and third generation adjuvant platforms but will also become the only adjuvant supplier in the world with an aseptic and GMP-certified manufacturing site for vaccine adjuvants.

Croda will leverage its own dedicated global sales network to accelerate Biosector’s growth. Furthermore, the acquisition will enable Croda to better support their existing customers through increased breadth of offering and additional technical expertise in vaccine adjuvants.

Nick Challoner, President of Life Sciences at Croda commented: “Biosector is a rare asset in a high-value, fast-growing sector of the global pharmaceutical market. With an experienced team, Biosector brings world-class innovation and industry-leading manufacturing facilities. The opportunity to quickly build upon Biosector’s impressive track record via our global sales network is enormously exciting and we look forward to welcoming the team to Croda.”

Peter Tygesen, Managing Director Biosector, said: “Croda share our passion for exciting innovation. Under the Croda umbrella we look forward to continuing to grow and further establish our research and development into high-quality industry-leading adjuvant platforms.”

Read More

Related news

Specialist API CDMO acquired by GHO Capital

Specialist API CDMO acquired by GHO Capital

16 Mar 2019

Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

Read more 
Bringing next generation single-use sensor technologies to the life science market

Bringing next generation single-use sensor technologies to the life science market

14 Mar 2019

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

12 Mar 2019

Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

Read more 
Overcoming lyophilization challenges at Interphex 2019

Overcoming lyophilization challenges at Interphex 2019

10 Mar 2019

Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

Read more 
Catalent invests over $27 million to commercialize Zydis Ultra

Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Read more 
Novel systems for membrane chromatography

Novel systems for membrane chromatography

6 Mar 2019

Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.

Read more 
Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

5 Mar 2019

Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more